{"filings":[{"id":1997597,"accession_number":"0001437749-26-025252","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2026-07-31T21:20:29+00:00","items":["3.02","3.03","5.03","9.01"],"status":"ready","headline":"Catheter Precision raises $2.82M via Series C-4 preferred stock issuance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed sale of 2,821 shares of Series C-4 Convertible Preferred Stock at $1,000 stated value for gross proceeds of $2,821,000.","Issued pursuant to Additional Investment Right under March 9, 2026 Securities Purchase Agreement.","Proceeds to be used for working capital, general corporate purposes, and redemption of all outstanding Series B Convertible Preferred Stock.","Series C-4 Preferred ranks senior to common stock; conversion will dilute existing common holders.","Dawson James Securities acted as placement agent; offering exempt under Section 4(a)(2) and Rule 506(b)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1922077,"accession_number":"0001437749-26-024717","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K/A","filed_at":"2026-07-29T00:01:08+00:00","items":["9.01"],"status":"ready","headline":"Catheter Precision acquires FLYTE; acquired entity reports $4.8M net loss, going concern doubt","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["FLYTE (private aviation platform) had net loss of $4.8M on revenue of $986K for 2025, accumulated deficit $17.2M.","Auditor expresses substantial doubt about FLYTE's ability to continue as a going concern; cash only $26K as of Dec 31, 2025.","Catheter Precision acquired 100% of FLYTE on March 9, 2026; pro forma financials filed.","FLYTE's operating loss was $4.7M in 2025, with negative operating cash flow of $2.3M.","Acquisition includes Fly Flyte, Inc. and Ponderosa Air, LLC; Catheter Precision committed to provide financial support."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1666756,"accession_number":"0001437749-26-023639","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2026-07-15T21:15:00+00:00","items":["3.02","3.03","5.03","9.01"],"status":"ready","headline":"Catheter Precision raises $3.47M via Series C-3 Convertible Preferred Stock issuance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 3,470 shares of Series C-3 Convertible Preferred at $1,000 stated value for gross proceeds of $3,470,000.","Conversion price initially $0.632 per share, subject to floor of $0.35 and anti-dilution adjustments.","Beneficial ownership limitation set at 4.99% (holder may increase to 9.99% on 61 days' notice).","Dawson James Securities acted as placement agent; proceeds for working capital, loan repayment, general corporate.","Series C-3 ranks senior to common on dividends and liquidation; conversion will dilute existing common holders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":899757,"accession_number":"0001437749-26-019779","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2026-06-08T10:16:04+00:00","items":["1.01","9.01"],"status":"ready","headline":"Catheter Precision invests $1M in Volato Group, receives SOAR and flyExclusive shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Purchases 2,941,176 SOAR shares at $0.34/share ($1M) in a private placement.","Volato to deliver 451,901 freely tradeable flyExclusive shares valued at ~$1.1M as additional consideration.","Closing subject to customary conditions including no Material Adverse Effect and NYSE American approval.","Registration Rights Agreement requires Volato to file resale registration statement within 10 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":499476,"accession_number":"0001437749-26-017612","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2026-05-18T20:17:11+00:00","items":["2.02","9.01"],"status":"ready","headline":"Catheter Precision Q1 revenue up 200% to $432K; net loss cut to $1.7M; Flyte acquisition adds aviation revenue","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $432K (200% YoY) driven by medical device segment (+73%) and new Flyte aviation platform.","Net loss narrowed to $1.7M from $4.0M in Q1 2025; includes ~$560K non-cash charges.","Flyte acquisition generated $200K monthly revenue run rate within 22 days; fleet expanding to 5 jets by end of Q2 2026.","Medical device products in 15 countries; new clinical data on VIVO and LockeT presented at HRS congress.","Company now a dual-engine growth platform combining medical devices and aviation infrastructure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":432000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94941,"accession_number":"0001437749-26-013183","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2026-04-23T23:59:59+00:00","items":["3.02","3.03","5.03","9.01"],"status":"ready","headline":"Catheter Precision closes $3.47M Series C-2 preferred; issues $11M Series D for Flyte acquisition","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["3,470 shares of Series C-2 Preferred at $1,000 stated value sold for gross proceeds of $3,470,000.","11,028 shares of Series D Preferred ($11.03M stated value) issued to SEG Jets and Creatd for Fly Flyte acquisition.","Series C-2 conversion price $0.883/share, floor $0.35; Series D conversion price $1.1038/share, subject to reduction.","Stockholder approval obtained April 15, 2026; proceeds for working capital and general corporate purposes.","Beneficial ownership limitation initially 4.99%, can be increased to 9.99% on 61 days' notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94940,"accession_number":"0001437749-26-012393","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2026-04-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Catheter Precision shareholders approve reverse split (1:2-1:100) and preferred share issuances","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All six proposals passed at April 15 special meeting; 49.5% of outstanding shares voted.","Reverse stock split authorized at ratio between 1-for-2 and 1-for-100, at board's discretion.","Issuance of common stock underlying Series C-1, C-2, C-3, C-4 convertible preferred approved (690,693 for).","Issuance of shares underlying Series D and Series J convertible preferred also approved (~690,600 votes for each).","Approval of conversion price reduction for Series B convertible preferred stock (690,825 for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107679,"accession_number":"0001437749-26-010721","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Catheter Precision FY2025 rev +95% to $819K; net loss $17.2M; acquires Flyte aviation platform","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $819K in FY2025, up 95% from $420K in FY2024; gross margin improved to 92.3% from 90.0%.","Net loss of $17.2M in FY2025, of which $7.8M non-cash, compared to $16.6M net loss in FY2024.","Q4 2025 revenue $238K, up 60% YoY; net loss $5.3M ($3.5M non-cash) vs $5.6M in Q4 2024.","Acquired Flyte, a regional air mobility company, post-year-end; financing completed to support two-platform growth strategy.","CE Mark received for LockeT in April 2025; added 32 new customers across VIVO and LockeT platforms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107678,"accession_number":"0001437749-26-007380","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["1.01","3.02","3.03","5.03","9.01"],"status":"ready","headline":"Catheter Precision acquires 80% of Fly Flyte and Ponderosa Air for $11.6M; raises up to $39M in PIPE","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition of 80.02% of Fly Flyte, Inc. and 100% of Ponderosa Air from Creatd for $11.55M in cash and Series D preferred stock.","Private placement of Series C convertible preferred stock raises $1.85M at first close, potential additional raises up to $35.6M.","Proceeds used for restructuring legacy catheter business, potential sale of medical devices, and reducing cash burn.","Conversion prices start at $1.43, adjust to 80% of market with $0.35 floor, subject to stockholder approval.","Registration rights agreement filed to register resale of conversion shares within 30–60 days of closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107677,"accession_number":"0001437749-26-003940","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["1.01","3.02","5.03","7.01","9.01"],"status":"ready","headline":"Catheter Precision secures up to $36.5M institutional financing; converts $9M liabilities into equity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO David Jenkins exchanged royalty rights for ~9,490 shares of Series J Preferred Stock convertible into 6,083,005 common shares at $1.56, subject to stockholder approval.","ATM equity offering program terminated; no future equity lines or forward-priced agreements anticipated.","Short-term notes converted to long-term debt with maturities of 2-3 years.","Additional $9M in short and long-term liabilities converted into equity, strengthening balance sheet.","Up to $36.5M in institutional financing secured to expand market presence and advance growth initiatives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107676,"accession_number":"0001437749-26-003387","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2026-02-06T23:59:59+00:00","items":["1.01","3.02","3.03","5.03","9.01"],"status":"ready","headline":"Catheter Precision raises $2.18M in private placement, acquires 19.98% stake in FLYTE for $5.25M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Initial closing of private placement yields $2.18M; additional closings could raise up to ~$44.6M total.","Issues Series C-1 convertible preferred at $1.43/share; conversion price can reset to 80% of market price after stockholder approval.","Acquires 19.98% of Fly Flyte, Inc. (air-mobility) for $5.25M in Series D convertible preferred, contingent on stockholder approval.","Existing Series B preferred and warrants repriced to $1.78, generating $400k cash from warrant exercises.","Proceeds to repay debt, wind down legacy catheter business, and explore going-private or spin-off transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107675,"accession_number":"0001437749-26-000839","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Catheter Precision extends maturity of $1.5M in 8% promissory notes to 2028-2029","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Extended $500k note from CEO David A. Jenkins matured Jan 31, 2026, now due Jan 31, 2029.","Extended three FatBoy Capital notes totaling $500k from Jan 31, 2026, to Jan 31, 2029.","Extended Jenkins Family Charitable Institute $500k note from Jan 31, 2026, to Jan 31, 2028.","All notes carry 8% interest; amendments dated Dec 31, 2025, and effective same day."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124049,"accession_number":"0001437749-25-036000","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-11-21T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Catheter Precision terminates ATM equity facility after selling ~$4.0M of $4.3M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated ATM agreement with Ladenburg Thalmann effective November 24, 2025; no penalties.","Prior to termination, $4.0M of common stock sold under the $4.3M capacity.","Remaining $0.3M of at-the-market offering capacity is no longer available."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124048,"accession_number":"0001437749-25-035245","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Catheter Precision Q3 revenue up 135% to $226K; net loss down 45% to $2.25M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue Q3 2025: $226K, +135% YoY from $96K; nine-month revenue $581K, +114%.","GAAP net loss Q3 2025: $2.25M, 45% reduction from $4.12M in Q3 2024.","Nine-month net loss $11.4M vs $11.0M; non-cash charges $4.2M.","CE Mark approval for LockeT driving international interest; reorders in South Africa and first French VIVO order.","VIVO clinical studies completed in 2025; CEO expects major US and international expansion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":581000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124047,"accession_number":"0001437749-25-031036","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-10-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Shareholders approve increase in authorized shares to 500M for Catheter Precision","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting on Oct 10, 2025 had 43.1% quorum (641,616 of 1,487,266 shares outstanding).","Proposal 1: authorized common shares increased from 60M to 500M (497,162 for, 133,882 against).","Proposal 2: WithumSmith+Brown ratified as independent auditor for FY2026 (610,134 for).","Proposal 3: approval to adjourn meeting if needed passed (514,362 for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.15,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140726,"accession_number":"0001437749-25-027270","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Catheter Precision secures UK approval for LockeT; partners with distributor HC21","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["LockeT suture retention device approved for commercialization in the UK; received CE Mark in May 2025.","Exclusive distribution agreement with HC21 (€180M revenue, 500+ employees across UK and Ireland).","LockeT aims to enhance patient comfort, enable earlier discharge, and help NHS reduce waiting lists.","Fatih Ayoglu (Sales Manager EMEA & APAC) highlighted potential to free up hospital capacity and accelerate patient throughput."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140725,"accession_number":"0001437749-25-027153","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-08-15T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Catheter Precision effects 1-for-19 reverse stock split effective August 15, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at ratio of 1-for-19; effective 12:01 a.m. ET on August 15, 2025.","Outstanding shares reduced from ~23,327,516 to ~1,227,764; no change to authorized shares (60M common).","Stock continues trading under symbol VTAK with new CUSIP 74933X 708; no fractional shares issued.","Proportionate adjustments made to per-share exercise prices and shares underlying outstanding options, warrants, and preferred stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140724,"accession_number":"0001437749-25-025935","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Catheter Precision Q2 revenue up 128% YoY to $212K; net loss $5.4M with $3.2M non-cash","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $212K for Q2 2025 vs $93K in Q2 2024, 128% increase; sequential growth 48%.","Net loss $5.4M for Q2 includes $3.2M non-cash charges; cash $838K at June 30.","Received CE Mark for LockeT product; European sales expected to start in Q3 2025.","Completed acquisition of Cardionomic heart failure assets via 82%-owned subsidiary Cardionomix.","Formed Kardionav JV for implant-based software to locate ventricular tachycardia ablation sites."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":355000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140723,"accession_number":"0001437749-25-023654","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-07-28T23:59:59+00:00","items":["5.07","8.01"],"status":"ready","headline":"Catheter Precision announces 1-for-19 reverse stock split effective August 15, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split ratio of 1-for-19 approved by board after shareholder authorization at July 25 annual meeting.","Pre-split shares reduced from ~23.3M to ~1.2M; no fractional shares issued, cash paid instead.","Split intended to maintain NYSE American minimum bid price requirement; CUSIP changes to 74933X708.","Annual meeting also approved issuance of up to 4.29M shares upon Series L warrant exercise and up to 8.57M shares on Series B preferred conversion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158462,"accession_number":"0001437749-25-020251","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Catheter Precision sees record Q2 LockeT sales; Italy distributor secured","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q2 2025 LockeT sales on track to be highest to date, outpacing Q2 2024 by more than $84,000.","Three hospitals — Montefiore, Eisenhower Health, Overland Park Regional — expected to issue >$100K in purchase orders each by end of 2025.","Secured new distributor in Italy; anticipates additional distributors in Spain, Portugal, and UK.","Live case scheduled June 16 with a key opinion leader at an Italian symposium to increase market awareness.","CEO cites expanded existing customer usage and European expansion as drivers of revenue growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158461,"accession_number":"0001437749-25-019768","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Catheter Precision Board approves warrant to Ladenburg Thalmann for 257,143 shares at $0.5424","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Warrant issued to Ladenburg Thalmann as partial compensation for pipe financing closed May 12, 2025.","Exercise requires stockholder approval at annual meeting on July 25, 2025; warrant expires June 6, 2030.","Warrant and underlying shares are unregistered under the Securities Act of 1933."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158460,"accession_number":"0001437749-25-019731","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Catheter Precision terminates Chief Commercial Officer; CEO assumes role temporarily","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Marie-Claude Jacques' employment as CCO discontinued effective June 2, 2025.","CEO David Jenkins will serve as interim CCO until a replacement is hired.","No further details on reason for departure or timeline for search provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158459,"accession_number":"0001437749-25-018985","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Catheter Precision details pro forma dilution to new investors at $1.25/share in ATM offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Historical net tangible book value as of Mar 31, 2025: $(15.8)M or $(1.71)/share; after offering: $(14.6)M or $(0.95)/share.","ATM offering assumes 4,333,333 shares at $0.30/share (May 14 close), net proceeds $1.2M; dilution to new investors $(1.25)/share.","Pro forma adjustments include 1,748,666 shares issued in April 2025; total outstanding after offering ~15.4M shares.","As of Mar 31, 2025, 17.4M warrants (weighted avg exercise $2.20) and 2.2M options outstanding represent additional dilution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158458,"accession_number":"0001437749-25-017634","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Catheter Precision enters ATM agreement to sell up to $1.3M of common stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATM agreement with Ladenburg Thalmann allows sale of up to $1.3M of common stock on NYSE American.","Proceeds will be used for operations and working capital; company has no obligation to sell any shares.","Ladenburg receives 3.0% commission on gross proceeds; agreement ends upon sale of all shares or by 5-day notice.","Shares are issued under existing S-3 registration statement (File No. 333-284217) effective Jan 22, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158457,"accession_number":"0001437749-25-017616","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Catheter Precision Q1 revenue up 74% to $143K, net loss $4.0M; cash $450K","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $143K vs $82K YoY (+74%); net loss $4.0M including $1.2M non-cash charges.","Cash $450K at March 31; after quarter end secured $1.5M private placement from institutional investors.","Acquired Cardionomics assets via 82%-owned subsidiary Cardionomix, including CPNS system for ADHF.","Acquired PeriKard, LLC (pericardial access kit); first U.S. patent allowed for LockeT device.","Clinical data presented at HRS 2025: VIVO 94% accurate, LockeT safe/effective in 139-patient study."],"consensus_eps_estimate":-3.876,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":143000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158456,"accession_number":"0001437749-25-016188","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["1.01","2.01","3.02","3.03","5.03","9.01"],"status":"ready","headline":"Catheter Precision raises $1.5M cash, issues 3,000 Series B Preferred shares and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Series B Preferred: 3,000 shares at $1,000 stated value; 1,500 sold for $1.5M cash, 1,500 issued for QHSLab notes.","Cash investors: C/M Capital (600 shares, 1.71M warrants), WVP/C/M Capital (400 shares, 1.14M warrants).","Mercer Street receives 2,000 Series B shares and 1.43M warrants in exchange for ~$1.6M defaulted QHSLab notes.","Conversion price $0.35/share; ~2,858 common shares per preferred share; warrants $0.50, 5.5-year term, callable above $1.50 VWAP.","Stockholder approval needed for conversion beyond 19.99% of outstanding and warrant exercise; meeting July 25, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158455,"accession_number":"0001437749-25-015488","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["1.01","2.03","2.01","3.02","7.01","9.01"],"status":"ready","headline":"Catheter Precision subsidiary acquires Cardionomic's heart failure assets for 1M shares and $1.5M note","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Cardionomix purchased CNPS System patents/trademarks for heart failure; closed May 5, 2025.","Consideration: 1M restricted VTAK shares and $1.5M note at 4% due May 2028.","Cardionomix minority stakes: CEO Jenkins (5%), FatBoy Capital (7%), others; requires development financing.","Company seeking additional financing including ATM offering; warns of dilution.","Assets acquired 'AS IS'; Cardionomix has no other significant assets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158454,"accession_number":"0001437749-25-012731","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-04-23T23:59:59+00:00","items":["1.01","2.03","2.01","2.02","8.01","3.02","9.01"],"status":"ready","headline":"Catheter Precision acquires heart failure device assets; Q1 revenue up 73% to $142k","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Subsidiary Cardionomix buys patents/trademarks for Cardionomic's CPNS System (acute decompensated heart failure).","Purchase price: 1M restricted VTAK shares plus a $1.5M promissory note (4% interest, 3-year maturity).","Closing conditions include NYSE American listing approval; deal must close by July 21, 2025.","Preliminary Q1 2025 revenue $142k vs $82k YoY (+73%).","Company warns it needs additional financing to develop assets; dilution expected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158453,"accession_number":"0001437749-25-012172","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-04-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Catheter Precision subsidiary seeks to buy heart-failure assets from Cardionomic","summary_kind":"llm","event_type":"m_and_a","confidence":"medium","bullets":["Subsidiary Cardionomix would acquire CPNS System assets for 1M restricted VTAK shares and $1.5M promissory note.","Cardionomix is 82% owned by VTAK; CEO David Jenkins holds 5% directly and 7% via FatBoy Capital.","Target closing in first half of Q2 2025; no signed agreement and no guarantee deal will close.","Purchased assets are on 'AS IS' basis; subsidiary will need substantial future financing to develop them.","Cardionomic, Inc. ceased operations; assets assigned for benefit of creditors to Seller LLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158452,"accession_number":"0001437749-25-010469","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-04-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Catheter Precision FY2024 revenue $420K, net loss $16.6M; Q4 rev $149K up 55% QoQ","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year 2024 revenue $420 thousand; Q4 2024 revenue $149 thousand, sequential increase of 55% over Q3.","Net loss for 2024 was $16.6 million, of which $7.5 million were non-cash charges; Q4 net loss $5.6 million.","LockeT vascular closure device first sales began Q2 2024 and grew sequentially; 26 institutions evaluated by year-end.","CE Mark for LockeT anticipated Q2 2025 with EU sales expected to start Q3 2025.","New Chief Commercial Officer appointed Q2 2024; majority of sales team replaced and trained by Q3 2024."],"consensus_eps_estimate":-3.876,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":143000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176834,"accession_number":"0001437749-25-007263","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-03-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Catheter Precision furnishes March 2025 investor presentation; no details available","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company filed an investor presentation dated March 2025 as Exhibit 99.1.","Presentation content is an image exhibit; no specific financial or operational data extracted.","No material new information can be determined from the furnished exhibit.","Stock continues trading on NYSE American under ticker VTAK."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176833,"accession_number":"0001437749-25-002726","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-02-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Catheter Precision awards 700,000 incentive stock options to CEO and CCO at $0.42","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO David Jenkins received options for 450,000 shares; 90,000 vested immediately, 120,000 vest each Jan 2026–2028.","CCO Marie-Claude Jacques received 250,000 options: half time-vesting over 5 years, half performance-vesting based on Q1–Q4 2025 sales targets.","Exercise price $0.42 per share; 10-year term; granted under the 2023 Executive Incentive Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176832,"accession_number":"0001437749-25-001385","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-01-17T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"Catheter Precision stockholders approve share issuance, authorized share increase, and equity plan expansion","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approved issuance of up to 10.7M shares upon exercise of Series K Warrants; 1.4M for, 833K against, 1.9M broker non-votes.","Approved amendment to increase authorized common shares from 30M to 60M; 2.8M for, 1.4M against.","Approved additional 1.5M shares for 2023 Equity Incentive Plan; 1.8M for, 426K against, 1.9M broker non-votes.","Ratified WithumSmith+Brown as auditor for FY2025; 3.7M for, 434K against, 23K abstain.","Legal opinion condition on authorized share increase satisfied; revised opinion filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176831,"accession_number":"0001654954-25-000174","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-01-07T23:59:59+00:00","items":["3.02","5.02"],"status":"ready","headline":"Catheter Precision appoints Philip Anderson as CFO, grants 500K stock options","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Philip Anderson appointed CFO effective Jan 6, 2025, replacing interim CFO Margrit Thomassen who becomes Controller.","Compensation: $200k base salary, discretionary bonus, and option grant of 500,000 shares at $0.53, vesting monthly over 3 years.","Anderson previously CFO at Heritage Distilling, Crown Electrokinetics, Kubient; retired from Nov 2022 to Dec 2024.","Stock options issued under Section 4(a)(2) as inducement to accept employment; no family or discloseable relationships."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193637,"accession_number":"0001654954-24-014464","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Catheter Precision posts Q3 net loss $4.1M, revenue $96K; warrants raise $4.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Sales revenue for Q3 2024 was ~$96K, net loss $4.1M (including $1.7M non-cash charges); nine-month net loss $11.0M.","Cash at Sept 30 was $1.3M; on Oct 25, 2024, warrant exercise raised gross proceeds of $4.9M.","Company has 87 hospitals in pipeline; 32 institutions in ongoing evaluations; CE Mark for LockeT expected by end of Q1 2025.","Commercial team includes new CCO Marie-Claude Jaques; VIVO procedures ongoing in multiple European countries.","Over 130 patients enrolled in LockeT II comparative study; initial LockeT study published in JCE in August."],"consensus_eps_estimate":-34.884,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":271000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193634,"accession_number":"0001654954-24-013701","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K/A","filed_at":"2024-11-04T23:59:59+00:00","items":["1.01","3.02","3.03","9.01"],"status":"ready","headline":"Catheter Precision reprices seven warrant series to $0.70, expects $3.7M from inducement exercises","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reduced exercise price of Series E, F, G, H, I warrants from $1.00/$30/$40 to $0.70 per share on Oct 24, 2024.","Inducement letters for immediate exercise of up to 5.3M warrants; expects ~$3.7M gross proceeds.","Pro forma shares outstanding after exercise: ~10.8M; earlier received $1.185M from 1.185M warrants at original terms.","New Series K warrants issued at $0.70, 200% coverage, 5.5-year term subject to stockholder approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193636,"accession_number":"0001654954-24-013502","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Catheter Precision waives beneficial ownership limit for insider warrant holder; 235,000 shares issued for $23.50","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Waiver granted to Jenkins Family Charitable Institute (trustee is CEO's daughter) to exercise 235,000 pre-funded warrants fully.","Prior 9.99% beneficial ownership cap removed; Institute now holds 6.32% of common stock post-exercise.","Aggregate exercise price paid: $23.50 ($0.0001 per share).","Waiver approved in advance by Company's Board Audit Committee due to related-party nature.","Warrants originally issued in September 2024 underwritten public offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193635,"accession_number":"0001654954-24-013313","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2024-10-25T23:59:59+00:00","items":["1.01","3.02","3.03","8.01","9.01"],"status":"ready","headline":"Catheter Precision raises $4.9M gross via warrant repricing; issues new Series K warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Total gross proceeds of $4.9M, including $3.7M from warrant repricing and $1.185M from prior exercises.","Exercise price reduced from $1.00/$30/$40 to $0.70 per share for Series E, F, G, H, I warrants.","New Series K warrants issued for 200% of exercised shares, $0.70 exercise price, 5.5-year term, exercisable only after shareholder approval.","Pro forma shares outstanding approximately 10.8 million after warrant exercises.","Ladenburg Thalmann served as exclusive warrant inducement agent with an 8% cash fee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209957,"accession_number":"0001654954-24-011589","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2024-09-06T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Catheter Precision closes $3.6M public offering with warrants; net proceeds ~$2.6M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering comprised of 805,900 common units at $1.00/unit and 2,773,000 pre-funded units at $0.9999/unit.","Each unit includes a share (or pre-funded warrant at $0.0001), Series H, I, and J warrants all exercisable at $1.00.","Underwriters partially exercised overallotment, adding 458,623 common stock units to the offering.","Estimated net proceeds to company after discounts and expenses are approximately $2.6 million.","Post-closing shares outstanding were 2,656,652; by Sep 5, 2024, reached 2,804,152 on further warrant exercises."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209956,"accession_number":"0001654954-24-011150","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2024-08-27T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Catheter Precision amends $1.5M promissory notes: maturity to Jan 2026, rate to 12%","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Extended maturity of five 8% short-term notes from Aug 30, 2024 to Jan 31, 2026.","Interest rate raised from 8% to 12% effective Aug 31, 2024; interest through Aug 30 due.","Notes total $1.5M: $500k from CEO David Jenkins, $500k from Jenkins Trust, $500k from FatBoy Capital.","All holders are related parties: CEO, his family trust, and an affiliate he controls.","Amendments reflect near-term liquidity need; higher cost and extended debt terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209955,"accession_number":"0001654954-24-010758","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2024-08-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Catheter Precision Q2 revenue $93K, net loss $4.2M; cash only $16K at June 30","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $93K, H1 $175K; net loss Q2 $4.2M, H1 $6.9M.","Cash at June 30 just $16K; rose to $330K by Aug 12 but remains extremely low.","First commercial LockeT sales in US: $38K in both Q2 and H1; 23 hospitals scheduling evaluations.","Total assets $26M, shareholders' equity $14.3M as of June 30.","14 new sales/clinical hires; VIVO evaluation started in Italy; VIVO EU Registry completed in June."],"consensus_eps_estimate":-50.9694,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":175000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209954,"accession_number":"0001654954-24-009649","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2024-07-30T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Catheter Precision borrows $500K from CEO-related trust at 8%, due Aug 30, 2024","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Jenkins Family Charitable Institute (CEO David A. Jenkins is settlor, his daughter is trustee) lends $500K via 8% promissory note maturing Aug 30, 2024.","This brings total related-party short-term notes (Jenkins/FatBoy Capital) to $1.5M, all due Aug 30, 2024.","Note is unsecured, contains standard events of default; proceeds used for general corporate purposes.","CEO Jenkins and affiliates hold over 10% of common stock, convertible preferred, options, and royalty rights on LockeT device sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209953,"accession_number":"0001654954-24-009421","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2024-07-25T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Catheter Precision converts all Series A Preferred; no shares remain outstanding","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On July 23, 2024, 400 Series A Preferred shares converted into 25,000 common shares.","Following conversion, no Series A Preferred shares remain outstanding.","Common shares issued under Section 3(a)(9) exemption and registered on Form S-1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209952,"accession_number":"0001654954-24-009309","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2024-07-23T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Catheter Precision gets $100K CEO loan at 8% due Aug 30, 2024, adding to prior $900K","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Entity controlled by CEO David Jenkins loans $100,000 via 8% promissory note due August 30, 2024.","Note issued to FatBoy Capital LP, which is controlled by Jenkins; he owns >10% of common stock.","This loan adds to $500K (May 2024) and $400K (June/July 2024) in prior related-party loans, totaling $1M.","Repayment expected from proceeds of pending S-1 registration statement securities sale.","Note includes customary default provisions; interest accrues at 8% per annum on 30/360 basis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209951,"accession_number":"0001654954-24-008907","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2024-07-12T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Catheter Precision files 1-for-10 reverse stock split; effective July 15, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split ratio of 1-for-10; shares outstanding reduce from ~9.0M to ~901k.","Authorized common stock reduced from 300M to 30M shares concurrently.","No fractional shares issued; cash paid for fractional interests; CUSIP changes to 74933X 609.","Proportionate adjustments to stock options, warrants, and preferred stock conversion terms.","Stock symbol remains VTAK; trading on NYSE American on split-adjusted basis from July 15."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209950,"accession_number":"0001654954-24-008787","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2024-07-10T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Catheter Precision shareholders approve reverse stock split, authorize share decrease","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["James Caruso and Andrew Arno elected as Class III directors with ~2.6M votes each.","Amendment to reduce authorized common stock approved by ~4.07M votes.","Reverse stock split (1:5 to 1:15) authorized by ~3.99M votes.","2M additional shares for 2023 Equity Incentive Plan approved by ~2.36M votes.","Nonbinding vote on executive compensation set to every three years based on shareholder preference."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209949,"accession_number":"0001654954-24-008613","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2024-07-03T23:59:59+00:00","items":["2.02","3.02","8.01","9.01"],"status":"ready","headline":"Catheter Precision reports Q2 revenue of $94,840; approves 1-for-10 reverse stock split","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary Q2 2024 revenue $94,840, including first LockeT sales ($40,500) and VIVO ($54,340).","Six-month 2024 revenue $176,923; 15% sequential quarter-over-quarter growth.","Board approved 1-for-10 reverse stock split effective July 15, 2024; shares reduce from 8.4M to ~839K.","Series A Preferred conversion issued 814,228 common shares on July 1, 2024.","New CCO Marie Claude Jaques hired in May; sales pipeline growing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209948,"accession_number":"0001654954-24-008484","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2024-07-01T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Catheter Precision receives $250K 8% note from CEO entity due Aug 30, 2024","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Entity controlled by CEO David A. Jenkins loans $250K at 8% interest, maturing August 30, 2024.","Note adds to $500K loan in May 2024 and $150K loan in June 2024 from same source.","Proceeds from S-1 securities sale expected to repay the note.","Jenkins and affiliates hold >10% common stock, convertible preferred, stock options, and 11.77% royalty on LockeT sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228145,"accession_number":"0001654954-24-008238","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2024-06-26T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Catheter Precision secures $150K 8% short-term note from CEO's entity due Aug 30, 2024","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["CEO David A. Jenkins' entity FatBoy Capital LP loans $150,000 at 8% interest, maturing August 30, 2024.","Loan is in addition to $500,000 loaned by Jenkins in May 2024; repayment expected from S-1 securities proceeds.","Note accelerates on customary defaults; Jenkins holds >10% common stock, convertible preferred shares, and 11.77% royalty rights.","Missiaen Huck, CEO's daughter, serves as non-executive COO; related-party details in proxy filed May 16, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228144,"accession_number":"0001654954-24-007260","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"CEO loans Catheter Precision $500K at 8%; enters royalty agreement for LockeT device","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["CEO David Jenkins loaned $500,000 via 8% promissory note due August 30, 2024.","Royalty agreement with co-inventor Auston Locke: 5% net sales of LockeT device until $1M, then 2% up to $10M; ends Dec 31, 2033 or patent expiry.","Jenkins and affiliates hold >10% common stock, Series X preferred convertible into >8M shares, and 11.77% royalty on LockeT sales.","Missiaen Huck, Jenkins' adult daughter, serves as non-executive COO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2024-06-03T23:59:59+00:00|228144"}